Why the study?
Does Akt signaling through GSK-3beta, mTOR, and Foxo1 regulate human skeletal muscle hypertrophy and atrophy during resistance training and de-training?
Does Akt signaling through GSK-3beta, mTOR, and Foxo1 regulate human skeletal muscle hypertrophy and atrophy during resistance training and de-training?
Akt signaling pathways involving GSK-3beta, mTOR, and Foxo1 are associated with both hypertrophy and atrophy processes in human skeletal muscle.
Answers are grounded in this paper and cite their sources.
Akt signaling tracks with human muscle hypertrophy and atrophy; extends animal data but remains hypothesis-generating for clinical translation.
Skeletal muscle size is tightly regulated by the synergy between anabolic and catabolic signalling pathways which, in humans, have not been well characterized. Akt has been suggested to play a pivotal role in the regulation of skeletal muscle hypertrophy and atrophy in rodents and cells. Here we measured the amount of phospho-Akt and several of its downstream anabolic targets (glycogen synthase kinase-3beta (GSK-3beta), mTOR, p70(s6k) and 4E-BP1) and catabolic targets (Foxo1, Foxo3, atrogin-1 and MuRF1). All measurements were performed in human quadriceps muscle biopsies taken after 8 weeks of both hypertrophy-stimulating resistance training and atrophy-stimulating de-training. Following resistance training a muscle hypertrophy ( approximately 10%) and an increase in phospho-Akt, phospho-GSK-3beta and phospho-mTOR protein content were observed. This was paralleled by a decrease in Foxo1 nuclear protein content. Following the de-training period a muscle atrophy (5%), relative to the post-training muscle size, a decrease in phospho-Akt and GSK-3beta and an increase in Foxo1 were observed. Atrogin-1 and MuRF1 increased after the hypertrophy and decreased after the atrophy phases. We demonstrate, for the first time in human skeletal muscle, that the regulation of Akt and its downstream signalling pathways GSK-3beta, mTOR and Foxo1 are associated with both the skeletal muscle hypertrophy and atrophy processes.
No takes yet. Share an insight, caveat, or question.
Léger et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: